Form 4: Vaxcyte COO Jim Wassil Reports Equity Transactions

Vaxcyte's Chief Operating Officer, Jim Wassil, reported multiple equity transactions including RSU grants, stock option awards, and shares withheld for taxes.

Summary

• Jim Wassil, Chief Operating Officer of Vaxcyte, Inc. (PCVX), reported several transactions involving the company's common stock and stock options.
• On February 26, 2026, Wassil acquired 32,045 shares of common stock underlying restricted stock units (RSUs) at a price of $0. These RSUs vest as to 1/4 on September 7, 2026, and 1/8 every six months thereafter.
• On February 27, 2026, an additional 5,102 RSUs were acquired at $61.74 per share, fully vested upon grant, as an election in lieu of a cash bonus.
• Shares were surrendered to the Issuer to cover tax withholding obligations: 1,900 shares on February 27, 2026, at $61.74; 898 shares on February 28, 2026, at $61.98; and 1,009 shares on March 2, 2026, at $61.98.
• Wassil also acquired 53,566 stock options on February 26, 2026, with an exercise price of $60. These options vest as to 1/48 of the shares on March 26, 2026, and 1/48 monthly thereafter, expiring on February 26, 2036.
• Following these transactions, Jim Wassil beneficially owns 175,188 shares of common stock and 53,566 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting routine executive compensation that aligns management's interests with long-term company performance through significant equity awards.

Positives

• Acquisition of 32,045 restricted stock units (RSUs) at a $0 price, representing future equity ownership.
• Acquisition of 5,102 fully vested RSUs in lieu of a cash bonus, indicating management's confidence and preference for equity.
• Grant of 53,566 stock options with a $60 exercise price, providing long-term incentive and aligning executive interests with shareholder value creation.

Negatives

• Disposition of 3,807 shares (1,900, 898, and 1,009 shares) to cover tax withholding obligations related to RSU vesting, which is a common but dilutive event for the executive's direct holdings.

Future Outlook

The filing details future vesting schedules for restricted stock units and stock options, indicating a long-term incentive structure for the Chief Operating Officer. The RSUs acquired on February 26, 2026, will vest quarterly and semi-annually through future dates, and the stock options will vest monthly over several years.

Industry Context

StockSavvy.ai notes that these transactions are typical for executive compensation packages in the biotechnology and pharmaceutical sectors, aiming to align management's long-term interests with shareholder value through equity ownership and performance-based incentives.

Stakeholder Impact

• Shareholders: The equity awards align the Chief Operating Officer's financial interests with the long-term performance of the company, potentially fostering greater commitment to increasing shareholder value.
• Employees: These transactions are part of a standard executive compensation framework, which can set a precedent for other senior management incentives.

Next Steps

• Continued vesting of 32,045 RSUs, with 1/4 vesting on September 7, 2026, and 1/8 every six months thereafter.
• Continued monthly vesting of 53,566 stock options, with 1/48 vesting on March 26, 2026, and monthly thereafter.

Key Dates

Recommendation

This Form 4 details routine executive compensation and tax-related transactions. While the acquisition of RSUs and stock options is a positive sign of executive alignment with shareholder interests, it does not provide new fundamental information about the company's operational or financial performance to warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals.

Keywords

Vaxcyte, PCVX, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Equity Award